Forte Biosciences, Inc.

NasdaqCM:FBRX Stock Report

Market Cap: US$33.2m

Forte Biosciences Future Growth

Future criteria checks 0/6

Forte Biosciences is forecast to grow revenue at 75.2% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate75.2%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Dec 2024

Recent future growth updates

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

Earnings and Revenue Growth Forecasts

NasdaqCM:FBRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/AN/AN/AN/A1
12/31/2026N/AN/AN/AN/A1
12/31/2025N/AN/AN/AN/A2
12/31/2024N/AN/AN/AN/A2
9/30/2024N/A-34-30-30N/A
6/30/2024N/A-36-31-31N/A
3/31/2024N/A-32-30-30N/A
12/31/2023N/A-31-29-29N/A
9/30/2023N/A-30-23-23N/A
6/30/2023N/A-24-16-16N/A
3/31/2023N/A-18-11-11N/A
12/31/2022N/A-14-8-8N/A
9/30/2022N/A-12-9-9N/A
6/30/2022N/A-17-12-12N/A
3/31/2022N/A-19-15-15N/A
12/31/2021N/A-22-17-17N/A
9/30/2021N/A-23-17-17N/A
6/30/2021N/A-20-20-20N/A
3/31/2021N/A-49-20-20N/A
12/31/2020N/A-46-18-18N/A
9/30/2020N/A-43-15-15N/A
6/30/2020N/A-39-8-8N/A
3/31/2020N/A-5-5-5N/A
12/31/2019N/A-4-3-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if FBRX's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if FBRX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if FBRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: FBRX is forecast to have no revenue next year.

High Growth Revenue: FBRX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if FBRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 23:03
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Forte Biosciences, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Kumaraguru RajaBrookline Capital Markets
Keay NakaeChardan Capital Markets, LLC